Research ExplorerPublications[PSMA-PET/CT has to be performed in every patient with bioch...

[PSMA-PET/CT has to be performed in every patient with biochemical recurrence following radical prostatectomy for early tumor detection]

Standard

[PSMA-PET/CT has to be performed in every patient with biochemical recurrence following radical prostatectomy for early tumor detection]. / Kotzerke, J.; Bohmer, D.; Schlomm, T.; Maurer, T.; Beer, A. J.; Schmidberger, H.

In: NUKLEARMED-NUCL MED, Vol. 57, No. 3, 2018, p. 69-73.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research

Harvard

Kotzerke, J, Bohmer, D, Schlomm, T, Maurer, T, Beer, AJ & Schmidberger, H 2018, '[PSMA-PET/CT has to be performed in every patient with biochemical recurrence following radical prostatectomy for early tumor detection]', NUKLEARMED-NUCL MED, vol. 57, no. 3, pp. 69-73. https://doi.org/10.3413/Nukmed-2018030003

APA

Kotzerke, J., Bohmer, D., Schlomm, T., Maurer, T., Beer, A. J., & Schmidberger, H. (2018). [PSMA-PET/CT has to be performed in every patient with biochemical recurrence following radical prostatectomy for early tumor detection]. NUKLEARMED-NUCL MED, 57(3), 69-73. https://doi.org/10.3413/Nukmed-2018030003

Vancouver

Kotzerke J, Bohmer D, Schlomm T, Maurer T, Beer AJ, Schmidberger H. [PSMA-PET/CT has to be performed in every patient with biochemical recurrence following radical prostatectomy for early tumor detection]. NUKLEARMED-NUCL MED. 2018;57(3):69-73. https://doi.org/10.3413/Nukmed-2018030003

Bibtex

@article{535cf5d924304a80bd847f11dffd603f,
title = "[PSMA-PET/CT has to be performed in every patient with biochemical recurrence following radical prostatectomy for early tumor detection]",
abstract = "The debate refers the known evidence for PSMA-PET/CT in biochemical recurrence of prostate cancer and consider carefully interdisciplinary in which situation which patient needs imaging to choose the adequate therapeutic option. General aspects for the care of cancer patients are taken into consideration.",
keywords = "Antigens, Surface/metabolism Early Detection of Cancer/methods Edetic Acid/analogs & derivatives Gallium Radioisotopes Glutamate Carboxypeptidase II/metabolism Humans Male Neoplasm Recurrence, Local/*diagnostic imaging/metabolism Oligopeptides Positron Emission Tomography Computed Tomography/*methods Prostatic Neoplasms/*diagnostic imaging/metabolism/surgery Radiopharmaceuticals",
author = "J. Kotzerke and D. Bohmer and T. Schlomm and T. Maurer and Beer, {A. J.} and H. Schmidberger",
note = "2567-6407 Kotzerke, Jorg Bohmer, Dirk Schlomm, Thorsten Maurer, Thomas Beer, Ambros J Schmidberger, Heinz Journal Article Germany Nuklearmedizin. 2018 Jun;57(3):69-73. doi: 10.3413/Nukmed-2018030003. Epub 2018 Jun 5.",
year = "2018",
doi = "10.3413/Nukmed-2018030003",
language = "Deutsch",
volume = "57",
pages = "69--73",
journal = "NUKLEARMED-NUCL MED",
issn = "0029-5566",
publisher = "Schattauer",
number = "3",

}

RIS

TY - JOUR

T1 - [PSMA-PET/CT has to be performed in every patient with biochemical recurrence following radical prostatectomy for early tumor detection]

AU - Kotzerke, J.

AU - Bohmer, D.

AU - Schlomm, T.

AU - Maurer, T.

AU - Beer, A. J.

AU - Schmidberger, H.

N1 - 2567-6407 Kotzerke, Jorg Bohmer, Dirk Schlomm, Thorsten Maurer, Thomas Beer, Ambros J Schmidberger, Heinz Journal Article Germany Nuklearmedizin. 2018 Jun;57(3):69-73. doi: 10.3413/Nukmed-2018030003. Epub 2018 Jun 5.

PY - 2018

Y1 - 2018

N2 - The debate refers the known evidence for PSMA-PET/CT in biochemical recurrence of prostate cancer and consider carefully interdisciplinary in which situation which patient needs imaging to choose the adequate therapeutic option. General aspects for the care of cancer patients are taken into consideration.

AB - The debate refers the known evidence for PSMA-PET/CT in biochemical recurrence of prostate cancer and consider carefully interdisciplinary in which situation which patient needs imaging to choose the adequate therapeutic option. General aspects for the care of cancer patients are taken into consideration.

KW - Antigens, Surface/metabolism Early Detection of Cancer/methods Edetic Acid/analogs & derivatives Gallium Radioisotopes Glutamate Carboxypeptidase II/metabolism Humans Male Neoplasm Recurrence, Local/diagnostic imaging/metabolism Oligopeptides Positron Emi

U2 - 10.3413/Nukmed-2018030003

DO - 10.3413/Nukmed-2018030003

M3 - SCORING: Zeitschriftenaufsatz

VL - 57

SP - 69

EP - 73

JO - NUKLEARMED-NUCL MED

JF - NUKLEARMED-NUCL MED

SN - 0029-5566

IS - 3

ER -